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This year’s Lasker DeBakey Clinical Research Award goes to Youyou Tu for the discovery of arte-
misinin and its use in the treatment of malaria—a medical advance that has saved millions of lives
across the globe, especially in the developing world.The future benefits of many seminal dis-
coveries in basic biomedical sciences
are not always obvious in the short run.
But for a handful of others, the impact
on human health is immediately clear.
Such is the case for the discovery by
Youyou Tu and colleagues of artemisinin
(also known as Qinghaosu) for treatment
of malaria. Artemisinin has been the front-
line treatment since the late 1990s and
has saved countless lives, especially
among the world’s poorest children.
The Promise of Project 523
The story of artemisinin began in the unlikely
atmosphere of the Cultural Revolution in
China as a government initiative to aid the
North Vietnamese in their war with the Unit-
ed States. During the war, malaria caused
by chloroquine-resistant Plasmodium
falciparum was a major problem that
spurred research efforts on both sides of
thebattlefield. In theUS, these efforts culmi-
nated in the discovery of mefloquine, a
compound that was curative in a single
dose against chloroquine-resistant para-
sites (Trenholmeetal.,1975).TheNorthViet-
namese, however, lacked a research infra-
structure and thus turned to China for help.
Under the instructions of ChairmanMao
and Premier Zhou, a meeting was held on
May 23, 1967 in Beijing to discuss the
problem of drug-resistant malaria para-
sites. This led to a secret nationwide pro-
gram called project 523, involving over
500 scientists in60 different laboratories
and institutes (Zhang et al., 2006).
Although the project’s short-term goal
was to produce antimalarial drugs that
could immediately be used in the battle-
field (by 1969 three treatments wereestablished), the project’s long-term goal
was to search for new antimalarial drugs
by screening synthetic chemicals and by
searching recipes and practices of tradi-
tional Chinese medicine.
Because this work was considered
amilitary secret, no communication about
the research to the outside world was al-
lowed, and in any case, during the tumult
of the Cultural Revolution, publication in
scientific journals was forbidden. For
these reasons, no one outside of project
523 knew about the work. Yet within
the project, information flowed freely
between the members of the various
research groups, and findings were pre-
sented at their frequent joint meetings.
Without a publication record, who
should be credited with the discovery of
artemisinin? The answer to this question
was not generally known when we (X.S.
and L.H.M.) began, in 2007, to delve into
the history of the discovery. Our findings
left no doubt that the major credit must
go to Youyou Tu, who was a principle
investigator at the Institute of ChineseMe-
teria Medica, China Academy of Chinese
Medical Sciences (CACAMS). In January
1969, Professor Tu led a team in screening
the literature and recipes of traditional
Chinese medicine under project 523. She
was chosen to present the work of project
523 for the first time in October 1981 in
Beijing to a World Health Organization
(WHO) visiting study group on chemo-
therapy of malaria (Tu, 1981).
From Ancient Recipe to Modern
Drug
During their search, Youyou Tu and
colleagues investigated more than 2,000Cell 146, Serecipes of Chinese traditional herbs,
compiling 640 recipes that might have
some antimalarial activity. They tested
in a rodent malaria model more than
200 recipes with Chinese traditional
herbs and 380 extracts from the herbs.
Among the promising results, extracts
from Artemisia annua L. (Qinghao), a
type of wormwood native to Asia, were
shown to inhibit parasite growth by
68%. Follow-up studies, however, only
achieved 12% to 40% inhibition. Pro-
fessor Tu reasoned that the low inhibition
could be due to a low concentration of the
active ingredient in the preparation and
began to improve the methods of extrac-
tion. After reading the ancient Chinese
medical description, ‘‘take one bunch of
Qinghao, soak in two sheng (0.4 liters)
of water, wring it out to obtain the
juice and ingest it in its entirety’’ in The
Handbook of Prescriptions for Emergency
Treatments by Ge Hong (283–343 CE)
during the Jin Dynasty, she realized that
traditional methods of boiling and high-
temperature extraction could damage
the active ingredient. Indeed, a much
better extract was obtained after switch-
ing from ethanol to ether extraction at
lower temperature.
However, the extract was still toxic.
Professor Tu then further removed from
the extract an acidic portion that con-
tained no antimalarial activity, leaving a
neutral extract with reduced toxicity and
improved antimalarial activity. The neutral
extract, termed extract number 191, was
tested in the mouse malaria, Plasmodium
berghei, and achieved 100% inhibition
in October 1971. She presented her find-
ings at a 523 meeting held in Nanjingptember 16, 2011 ª2011 Elsevier Inc. 855
Figure 1. The Antimalarial Drug Artemisinin (Qinghaosu)
Since the discovery of artemisinin from Artemisia annua L., a plant used in
traditional Chinese medicine, by Youyou Tu and colleagues, many derivatives
have been synthesized, including dihydroartemisinin, which is more active
than artemisinin. To protect this important antimalarial drug, combination
therapy with another antimalarial drug is the only treatment used today. The
future synthesis of new antimalarial drugs may be possible, originating from
the endoperoxide bridge that is required for artemisinin’s antimalarial activity
(Charman et al., 2011).on March 8, 1972, providing
some critical parameters for
other teams to quickly obtain
pure artemisinin crystals.
Although Tu’s team struggled
to obtain high-quality crystals
from the plant in the following
months, two teams (Zeyuan
Luo, Yunnan Institute of
Drug Research and the late
Zhangxing Wei, Shandong
Institute of Chinese Tradi-
tional Medicine), using the
information and methods she
used, soon obtained pure
crystals from A. annua L. that
were highly active against
rodent malaria parasites.
Tests in humans by Guoqiao
Li, Guangzhou University of
Chinese Traditional Medi-
cine, using the artemisinin
crystals from Yunnan Institute
of Drug Research showed
good activity against malaria
infection.
Interestingly, the paper de-
scribing artemisinin’s X-ray
crystal structure, pharmacol-
ogy, and efficacy against non-
severe and severe cerebral
malaria listed no specific au-
thors, who were identified
instead as the Qinghaosu
Antimalarial Coordinating Re-search Group (1979). The paper showed
that artemisinin is a sesquipene lactone
with an endoperoxide, and that the endo-
peroxide is required for its antimalarial
activity (Figure 1). In 1985, Klayman,
working in the US at the Walter Reed
Army Institute of Research (WRAIR),
described the isolation of the same com-
pound and its structure from Artemisia
annua (sweet wormwood), which grew
along the shores of the Potomac River.
Klayman pointed out that there are
few naturally occurring endoperoxides
described in plants. Although numerous
hydroxoperoxides had been tested at
WRAIR, none were found to have antima-
larial activity (Klayman, 1985).
Two clinical studies headed by Pro-
fessor Gouqiao Li compared artemisinin
and mefloquine. These studies were the
first to suggest that combination therapy
should be considered to prevent recur-
rence and development of resistance856 Cell 146, September 16, 2011 ª2011 Els(Jiang et al., 1982; Li et al., 1984). Artemi-
sinin works quickly within hours com-
pared tomefloquine’s slow parasite clear-
ance, but because of its short half-life,
artemisinin requires another drug in com-
bination to obtain a cure. Patients recov-
ered so quickly after taking artemisinin
that they would not continue treatment
after they felt better and thus were ulti-
mately not cured. Such incomplete treat-
ment may promote drug resistance. Li’s
group also developed suppositories con-
taining artemisinin to treat cerebral ma-
laria that are now being used in field
clinics in Africa. Shortening the time to
treatment by the use of suppositories
improves survival.
After learning of this important dis-
covery by the Chinese, Nick White, who
was working in Thailand as a professor
at Oxford, began the study of artemisinin
derivatives. He confirmed its rapid activity
and the need for a partner drug to clearevier Inc.the parasitemia and became
the primary proponent for the
use of artemisinin derivatives
in combination therapy, which
is now the standard treatment
worldwide. In 2010, he was
honored by the Canadian
Gairdner Award for this im-
portant work.
Project 523 developed, in
addition to artemisinin, a num-
ber of products that are used
in combination with artemisi-
nin, including lumefantrine,
piperaquine, and pyronari-
dine. Their success reflects
the unique spirit of collabora-
tion from a large number of
scientists and institutions in-
volved in the search for anti-
malarial drugs.
An Ongoing Battle
against Resistance
An important unanswerable
question is how effective arte-
misinin or its derivatives will
be in the future. We can per-
haps gain perspective from
the history of other antima-
larial drugs. The initial mor-
tality from malaria was ex-
tremely high throughout the
world before the introduction
of the last herbal medicine,quinine. Wherever it was introduced,
there was a marked decrease in mortality.
When the price of quinine decreased
in Italy, leading to the increased use
of quinine, the mortality markedly de-
creased. It is not surprising that when
P. falciparum became resistant to the
synthetic antimalarial drug chloroquine,
mortality in children rose dramatically.
Once the basis of resistance to chloro-
quine was identified as mutations in the
gene encoding the putative chloroquine
transporter in the food vacuole, PfCRT
(Fidock et al., 2000), it became evident
that the mutations had not originated in
Africa but were introduced from South-
east Asia (Wootton et al., 2002).
A major challenge to public health
officials in African countries is to decide
when to change their antimalarial drug
policy. Such decisions require a careful
review of efficacy given that the choices
available are limited. However, during
these transitions, deaths (particularly of
children) occur before the decision to
change regimens is made. After chloro-
quine, the next antimalarial drug to be
introduced to Africa was sulfadoxine-pyri-
methamine (Fansidar), which is a syn-
ergistic antimalarial combination. After
its introduction, Fansidar resistance, due
to mutations in both P. falciparum dihy-
drofolate reductase and dihydropteroate
synthetase, has been widely reported.
Likewise, resistance to mefloquine has
occurred in Asia, where it was introduced
as a stand-alone antimalarial drug. Unfor-
tunately, mefloquine resistance has also
undermined the efficacy of its combina-
tion treatment with Fansidar, called Fansi-
mef. Additionally, mefloquine is expensive
to produce and cannot fit the financial
needs of the African population.
The insistence that artemisinin deriva-
tives must be used in combination ther-
apy (Figure 1) may protect it from resis-
tance, at least for some time. This will
require careful evaluation of the efficacy
of the added drug to protect artemisinin.
The one hope is that the use of artemisinin
combination therapy will remain effective
and that mortality associated with a
change in drugs will be prevented.
We also face the question of what drug
to adopt next if resistance to artemisinin
becomes a problem. Resistance to arte-
misinin derivatives may be arising on the
Thai-Cambodian border (Dondorp et al.,
2009), evident in the longer time it takes
for treatment to clear parasites from the
blood than has been reported previously
or from other areas of Thailand. However,
a similar concentration of artemisinin as
originally used for the sensitive parasites
can kill the resistant parasites in vitro
and in vivo. Although there are disagree-
ments as to whether this indicates resis-
tance, the prudent approach is to assume
that it is early resistance and to try to limit
the spread of these parasites. This would
mirror earlier epidemiological patterns of
malarial drug resistance—for both chloro-
quine and pyrimethamine-sulfidoxine,
resistance originated in Southeast Asia
and later spread to Africa. Vigilance is
particularly warranted given that resis-
tance to antimalarial drugs can develop
rapidly. The one exception has been
quinine, in use for hundreds of years,
and resistance has only developed slowly
with the level of drug required for cureincreasing with time. Our hope is that
a similar course will be seen for the other
herbal medicine, artemisinin.
The Future of Antimalarial
Treatments
Efforts are ongoing to make other antima-
larial compounds based on the structure
of artemisinin and its mechanism of
action. It is known that artemisinin
requires hemoglobin digestion and the
release of iron containing heme, which
induces oxidative stress (Klonis et al.,
2011). As noted by Klayman (1985), there
are few natural products with an endoper-
oxide, and this peroxide also offers an
opportunity to make new antimalarial
drugs (Charman et al., 2011).
But who is going to develop these new
drugs? Artemisinin’s discovery was
spurred on by war, and it can be hoped
that more peaceful motivations will drive
the development of future malaria treat-
ments. Yet, malaria has not been a major
target of drug companies, which have
historically focused their efforts on more
profitable treatments for diseases prev-
alent in affluent countries. Filling this
gap, joint public-private companies,
such as theMedicines for Malaria Venture
(MMV), may prove a successful model
funding drug development. In addition,
modern approaches, such as high-
throughput screening a large number of
compounds, may also provide new leads
for antimalarial drugs.
Another question that is raised with any
treatment or control measure is, how
effective is it in reducing mortality? In
many areas of the world, two measures
of malaria control were introduced simul-
taneously: artemisinin combination ther-
apy and bednets treated with long-acting
pyrethroid insecticides. As a result, many
areas in Africa have shown a reduced
incidence of malaria, although a careful
analysis of the data fails to identify the
intervention that led to reduced disease
and, as a consequence, reduced death
(O’Meara et al., 2010). In recent years,
there has been a disturbing increase in
pyrethroid resistance by malaria vectors
in Africa (Ranson et al., 2011). A study in
Dielmo, Senegal, where transmission is
continuous at a high level because of a
stream that runs through the village from
an underwater spring, showed a great
reduction of disease after the introductionCell 146, Seof control methods, but this reduction was
followed by a recent rebound (Trape et al.,
2011), perhaps as a result of insecticide
resistance. If such resistance becomes
widespread, people will be completely
dependent on artemisinin combination
therapy for preventing disease and
death given that many have lost some of
their immunity as a result of the marked
reduction in malaria. As long as the
mosquito species that harbor the parasite
remain in Africa, such recurrences can be
expected.
Although the challenges of combating
malaria remain daunting, the discovery
of artemisinin by Youyou Tu and her
many colleagues in the Chinese scientific
community offers hope and is a great
achievement in the history of modern
medicine.
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